ambrey-geneticsambry-geneticsbmi-healthcareBMIbrca-test-ukbrcabupacall-us-icon cardio-dxcolordowndownloademail-us-icon facebook-icon-hover facebook-icon facebookforwardhalio-dxhca-healthcareHCAhearthome-iconicon-burgericon-closeicon-githubicon-tick icon-twitterinstagram-icon-hover instagram-icon invitae-horizontalinvitae-verticallinkedIn-icon-hover linkedIn-icon nanostringnuffield-healthnuffieldoncodnaoncomarkribbonskylinetwitter-icon-hover twitter-icon veracytevideovitalityyoutube-icon-hover youtube-icon coloricon-github
SkylineDx MMprofiler<sup>TM</sup> logo

SkylineDx MMprofilerTM

Accurately measure the prognosis of patients with multiple myeloma and recommend the most appropriate treatment.

Enquire now

Measure a patient’s prognosis for multiple myeloma to guide appropriate treatment

MMprofilerTM is a prognostic test to help clinicians determine a patient’s level of risk for multiple myeloma and recommend the most appropriate treatment.

Patients are classed into standard or high risk using an innovative gene signature that profiles 92 genes. These results are then given a binary read-out SKY92 risk score, which is then reviewed in combination with current standard care markers to inform clinicians and patients of the aggressiveness of the disease and inform decision-making about treatment options.

The test is recommended in the newly diagnosed and relapsed/refractory multiple myeloma settings.

Why choose MMProfilerTM?

  • Accurately measures the prognosis of patients with multiple myeloma.
  • Offers patients the appropriate level and combination of treatments depending on their prognosis.
  • Eliminates expensive and potentially toxic treatment where the risks outweigh the benefits.
  • Predicts a patient’s response to a specific treatment.

This service is expected to be available in late 2023.

Diseases testedClose tab
  • Blood cancer, specifically multiple myeloma.
Genes tested forClose tab
  • 92 genes from malignant plasma cells.
Test resultsClose tab

Test results provide a binary classification, standard risk or high-risk, utilising the well-validated SKY92 gene signature.

Results will determine high-risk patients missed by established RISS and FISH strategies. As such, the test will support healthcare professionals, and patients in choosing the optimum combination of treatments, avoiding over – or undertreatment.

Results should be reviewed in combination with current standard care markers to inform healthcare professionals of the aggressiveness of the myeloma

Ordering informationClose tab

Who can order this test from Everything Genetic? Healthcare providers – this service is expected to be available in late 2023.

Turnaround time: Not currently available.

Preferred specimen collection:

  • Collect 5ml to 10ml bone marrow aspirate into Heparin (green top)/EDTA sample tube.
  • Store at ambient temperature.
  • Do not freeze or refrigerate.

Delivery information: Test kits will be sent out using a Royal Mail Tracked service unless otherwise arranged.

Clinical descriptionClose tab

Multiple myeloma is a blood cancer characterised by the clonal proliferation of plasma cells in the bone marrow. New treatments, such as lenalidomide, bortezomib and daratumumab, have been added to the therapeutic landscape, contributing to increased survival rates.

The clinical course of myeloma varies a lot between different patients. This variability is related to the unique properties of an individual’s cancer cells. MMprofilerTM can accurately determine whether a patient’s myeloma is standard or high risk so you can recommend the most appropriate treatment strategy.

MMprofilerTM is intended to be used as a prognostic test to determine the risk of disease progression in people diagnosed with myeloma. The implication for treatment based on the SKY92 result is at the clinician’s and patient’s discretion in line with established clinical guidelines.

Assay and technical information

MMprofiler is one of the only gene expression profile tests to be developed into a validated clinical test (Shah et al., 2020). The test is the only technology with CE-IVD approval for which a significant improvement in risk prediction has been demonstrated compared to current risk prediction in myeloma.

Service provided by